Sodium channel blockers

Details Sodium channel blockers Sodium channel blockers

2007-03-20

2007-03-20

Tucker, Zachary C. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S242000, C514S252110, C514S255050, C544S238000, C544S295000, C544S357000

Reexamination Certificate

active

10828329

ABSTRACT:
The present invention relates to compounds represented by formula (I):in which at least one of R3and R4is a group represented by formula (A):where the structural variables are defined herein. The compounds are useful for blocking sodium channels.

REFERENCES:
patent: 3313813 (1967-04-01), Cragoe, Jr. et al.
patent: 3472848 (1969-10-01), Cragoe, Jr. et al.
patent: 3539569 (1970-11-01), Pollack et al.
patent: 3544571 (1970-12-01), Cragoe, Jr. et al.
patent: 3573306 (1971-03-01), Shepard et al.
patent: 3625950 (1971-12-01), Cragoe, Jr.
patent: 3668241 (1972-06-01), Cragoe, Jr. et al.
patent: 3794734 (1974-02-01), Cragoe, Jr. et al.
patent: 3864401 (1975-02-01), Schultz et al.
patent: 3894065 (1975-07-01), Cragoe, Jr. et al.
patent: 3914253 (1975-10-01), Cragoe, Jr. et al.
patent: 3928624 (1975-12-01), Cragoe, Jr. et al.
patent: 3929872 (1975-12-01), Cragoe, Jr. et al.
patent: 3931239 (1976-01-01), Cragoe, Jr. et al.
patent: 3953476 (1976-04-01), Cragoe, Jr. et al.
patent: 3956374 (1976-05-01), Shepard et al.
patent: 3958004 (1976-05-01), Cragoe, Jr. et al.
patent: 3966966 (1976-06-01), Cragoe, Jr. et al.
patent: 3974212 (1976-08-01), Cragoe, Jr. et al.
patent: 3976681 (1976-08-01), Cragoe, Jr. et al.
patent: 3976686 (1976-08-01), Cragoe, Jr. et al.
patent: 3979361 (1976-09-01), Schultz et al.
patent: 3984465 (1976-10-01), Cragoe, Jr. et al.
patent: 3984552 (1976-10-01), Cragoe, Jr. et al.
patent: 3987091 (1976-10-01), Cragoe, Jr. et al.
patent: 3989749 (1976-11-01), Cragoe, Jr. et al.
patent: 3991087 (1976-11-01), Cragoe, Jr. et al.
patent: 3991106 (1976-11-01), Cragoe, Jr. et al.
patent: 4003927 (1977-01-01), Woltersdorf, Jr. et al.
patent: 4006180 (1977-02-01), Cragoe, Jr. et al.
patent: 4012524 (1977-03-01), Cragoe, Jr. et al.
patent: 4025625 (1977-05-01), Rooney et al.
patent: 4067980 (1978-01-01), Cragoe, Jr. et al.
patent: 4085117 (1978-04-01), Cragoe, Jr. et al.
patent: 4085211 (1978-04-01), Cragoe, Jr. et al.
patent: 4085219 (1978-04-01), Cragoe, Jr. et al.
patent: 4087526 (1978-05-01), Cragoe, Jr. et al.
patent: 4087542 (1978-05-01), Cragoe, Jr. et al.
patent: 4092414 (1978-05-01), Cragoe, Jr. et al.
patent: 4100294 (1978-07-01), Cragoe, Jr. et al.
patent: 4105769 (1978-08-01), Rooney et al.
patent: 4140776 (1979-02-01), Cragoe, Jr. et al.
patent: 4145551 (1979-03-01), Cragoe, Jr. et al.
patent: 4159279 (1979-06-01), Smith et al.
patent: 4163781 (1979-08-01), Cragoe, Jr. et al.
patent: 4163794 (1979-08-01), Cragoe, Jr. et al.
patent: 4177285 (1979-12-01), Cragoe, Jr. et al.
patent: 4181727 (1980-01-01), Cragoe, Jr. et al.
patent: 4196292 (1980-04-01), Woltersdorf, Jr. et al.
patent: 4237130 (1980-12-01), Cragoe, Jr. et al.
patent: 4237144 (1980-12-01), Cragoe, Jr. et al.
patent: 4246406 (1981-01-01), Cragoe, Jr. et al.
patent: 4277602 (1981-07-01), Woltersdorf et al.
patent: 4291050 (1981-09-01), Woltersdorf, Jr. et al.
patent: 4296122 (1981-10-01), Cragoe, Jr. et al.
patent: 4298743 (1981-11-01), Cragoe, Jr. et al.
patent: 4317822 (1982-03-01), Woltersdorf, Jr. et al.
patent: 4362724 (1982-12-01), Bock et al.
patent: 4401669 (1983-08-01), Cragoe, Jr. et al.
patent: 6475509 (2002-11-01), Boucher, Jr.
patent: WO 01/05773 (2001-01-01), None
Velly et al, “Effects of amiloride and its analogues on [3H]batrachotoxinin-A 20-α benzoate binding, [3H]tetracaine binding and 22 Na influx” European Journal of Pharmacology, vol. 149, No. 1-2, 1988, pp. 97-105.
Kellerman, D. “P2Y2 Receptor Agonists. A New Class of Medication Targeted at Improved Mucociliary Clearance” Chest, vol. 121(5), supplement, pp. 201S-205S.
R. Tarran et al., The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches,Molecular Cell, vol. 8, 149-158, Jul. 2001.
Michael R. Knowles et al.,Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease, Chapter 20, p. 301-316, 1992.
Louis Simchowitz et al.,An Overview of the Structure Activity Relations in the Amiloride Series, Chapter 2, p. 9-25, 1992.
J.R. Sabater et al., Aerosolization of P2v2-Receptor Agonists Enhances Mucociliary Clearance in Sheep,The American Physiological Society, p. 2191-2196, 1999.
Thomas R. Kleyman et al., Amiloride and Its Analogs as Tools in the Study of Ion Transport,The Journal of Membrane Biology, vol. 105, pp. 1-21, 1988.
Edward C. Taylor et al., A Facile Route to “Open Chain” Analogues of DDATHF,Heterocycles, vol. 28, No. 2, 1989.
Paul-Michael Windscheif et al., Substituted Dipyridlethenes and—ethynes and Key Pyridine Building Blocks,Synthesis, pp. 87-92, Jan. 1994.
Edward J. Cragoe, Jr.,The Synthesis of Amiloride and Its Analogs, p. 24-38, Chapter 3, 1992.
Jack H. Li, et al., Stereoselective Blockage of Amphibian Epithelial Sodium Channels by Amiloride Analogs,The Journal of Pharmacology and Experimental Therapeutics, vol. 267, No. 3, pp. 1081-1084, 1993.
Pallav L. Shah, M.D.,Chapter 7, Progress in the Treatment of Pulmonary Disease in Cystic Fibrosis, Annual Reports in Medicinal Chemistry, vol. 36, pp. 67-76, 2001.
Dieter Worlitzsch et al., Effects of Reduced Mucus Oxygen Concentration in Airway Pseudomonas Infections of Cystic Fibrosis Patients,The Journal of Clinical Investigation, Feb. 2002, vol. 109, No. 3, pp. 317-336.
Edward J. Cragoe, Jr., et al., Chapter 7: Diuretic Agents,Annual Reports in Medicinal Chemistry, 1966, p. 59-68.
Edward J. Cragoe, Jr., et al., Chapter 7: Diuretic Agents,Annual Reports in Medicinal Chemistry, 1965, p. 67-77.
Robert L. Smith, et al., Chapter 8: Diuretics,Annual Reports in Medicinal Chemistry, vol. 11, pp. 71-79, 1976.
Robert L. Smith, et al., Chapter 7: Diuretics,Annual Reports in Medicinal Chemistry, vol. 13, pp. 61-70, 1978.
Edward J. Cragoe, Jr., Structure-Activity Relationships in the Amiloride Series,Merck Sharp and Dohme Research Laboratories, 1979, pp. 1-20.
T.M. Cocks, et al., British Journal of Pharmacology, 95(1), pp. 67-76 (English) 1988.
Thomas R. Kleyman, et al., American Journal of Physiology, 260(2, Pt. 1), pp. C271-C276 (English), 1991.
K.E. Barrett, et al., Annu. Rev. Physiol. 2000; 62, pp. 535-572.
R.F. Epand, et al., British Journal of Cancer, 63(2), 247-51 (English) 1991.

Affiliated with

Also associated with

Rating

Sodium channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sodium channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sodium channel blockers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3758634